Biotech stalwart Biogen (BIIB) is up big in the early going in trading today, climbing some 40% on news that is Alzheimer's candidate aducanumab is not as dead as investors have thoughtNew data from its terminated Phase 3 study called EMERGE met the primary endpoint showing a statistically significant reduction in clinical decline at week 78 as me...
Read the full story and get access to the Real Money Pro trading floor.
There's no substitute for a trading floor to get great ideas, so Jim Cramer created a better one at Real Money and blogs there exclusively. We then added legendary hedge fund manager, Doug Kass, with his exclusive Daily Diary and best investing ideas. Staffed with more than 4 dozen investing pros, money managers, journalists and analysts, Real Money Pro gives you a flood of opinions, analysis and actionable trading advice found nowhere else, and allows you to interact directly with each expert.